DOC Price Prediction Next Week
Technical Analysis:
- RSI(14) at 41.25 indicates neutral to slightly oversold conditions
- MACD showing bearish momentum with -0.25 and negative histogram
- Price trading below all major moving averages (5,10,20,60,200-day SMAs)
- Bollinger Band Position (BBP) at 0.27 suggests downward pressure
Price Targets Based on Technical Levels:
- Fibonacci resistance levels: R1: $20.48, R2: $20.83, R3: $21.38
- Fibonacci support levels: S1: $19.37, S2: $19.03, S3: $18.47
- Pivot point: $19.93
Recent News Impact:
- RBC Capital maintained Buy rating with $25 price target
- BMO Capital issued Buy rating while Wells Fargo maintained Hold
- Company reported strong Q4 2024 results with revenue of $697.99M
- Upcoming ex-dividend date on 2/14/25 with quarterly dividend of $0.305
Price Prediction for Next Week: Based on technical indicators and recent news sentiment:
- Bearish Scenario (60% probability): Price likely to test S1 at $19.37
- Base Scenario (30% probability): Consolidation between $19.37-$19.93
- Bullish Scenario (10% probability): Bounce towards R1 at $20.48
Recommendation: SELL
- Current technical setup shows bearish momentum
- Price below all major moving averages indicates strong downtrend
- Despite positive analyst ratings, technical indicators suggest further downside potential
- Optimal selling point: Current market price around $19.75
- Stop loss: Place above R1 at $20.50 for risk management
DOC Similar Chart Price Prediction
The price of DOC is predicted to go up -14.45%, based on the high correlation periods with FBRX. The similarity of these two price pattern on the periods is 92.12%.
DOC
FBRX
Down: -14.45%Similarity: 92.12%
DOC Revenue Forecast
DOC EPS Forecast
DOC FAQs
What is bull’s view on DOC?
What is bear's view on DOC?
What is DOC revenue forecast for next quarter？
DOC VS S&P500
Healthpeak enjoys industry tailwinds, including an aging population and regulatory changes that expand the pool of participants in the healthcare system.
Healthpeak's diverse strategy allows it to consider a range of opportunities across property types and business models as a means for growth.
Healthpeak's expanding life science portfolio, currently experiencing all-time high occupancy and strong operating performance, could be an overlooked gem, especially after BioMed Realty's privatization.
DOC Analyst's Forecast
Amanda Sweitzer
Baird
Buy
2025-02-11
Price Target
$25 → $24
Upside
+22.39%
Baird analyst Wesley Golladay lowered the firm's price target on Healthpeak Properties to $24 from $25 and keeps an Outperform rating on the shares. The firm noted its Q4 results suggest the company is deploying capital om multiple fronts.
Connor Siversky
Wells Fargo
Hold
2024-12-10
Price Target
$23 → $22
Upside
+2.61%
Amanda Sweitzer
Baird
Buy
2024-10-30
Price Target
$24 → $25
Upside
+10.04%
